Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15402296 | 0.90 | ALDH1A1 (0.40) | LMNAFABP4FABP5TP53TDP1 | |
| SCHEMBL15375322 | 0.87 | FABP4 (0.44) | LMNAMAOBFABP4FABP5POLB | |
| SCHEMBL15402061 | 0.86 | MEN1 (0.44) | LMNAMAOBFABP4FABP5POLB | |
| SCHEMBL7969296 | 0.86 | MEN1 (0.42) | LMNAFABP4FABP5MAPK1L3MBTL1 | |
| SCHEMBL15402468 | 0.86 | SMN1; SMN2 (0.45) | MAOBMAPK1 | |
| SCHEMBL15401831 | 0.85 | MAOB (0.40) | MAOBCD274POLBESR1TP53 | |
| SCHEMBL28038430 | 0.85 | FABP4 (0.36) | LMNAMAOBFABP4FABP5CD274 | |
| SCHEMBL15402165 | 0.84 | FABP4 (0.42) | LMNAFABP4FABP5CD274FFAR1 | |
| SCHEMBL15402300 | 0.84 | FABP4 (0.42) | LMNAFABP4FABP5POLBTDP1 | |
| SCHEMBL15402214 | 0.84 | FABP4 (0.46) | LMNAMAOBFABP4FABP5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103588657-B | The manufacture method of phenylacetyl amines | 住友化学株式会社 | 2016-06-22 | — | — | CN | disclosed |
| EP-2397459-B1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8624062-B2 | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | MRPL21, AADAC, ARSA | LMNA 4708/4885MAOB 1169/4885FABP4 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.